|Bid||247.10 x 800|
|Ask||247.20 x 900|
|Day's Range||243.01 - 247.63|
|52 Week Range||198.64 - 258.45|
|Beta (5Y Monthly)||0.59|
|PE Ratio (TTM)||25.51|
|Earnings Date||Apr 25, 2022 - Apr 29, 2022|
|Forward Dividend & Yield||7.76 (3.19%)|
|Ex-Dividend Date||May 16, 2022|
|1y Target Est||249.25|
Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.
J&J's immunology mega-blockbuster loses exclusivity in the U.S. next year -- and Amgen's biosimilar is ready to capitalize.
Mirati (MRTX) seeks a nod for its lung cancer candidate adagrasib in the European Union. A regulatory filing in the United States is currently under the FDA review with decision pending this year-end.